miR‑155 inhibitor reduces the proliferation and migration in osteosarcoma MG‑63 cells

Lv,Huicheng; Guo,Jun; Li,Siqin; Jiang,Dianmin

doi:10.3892/etm.2014.1942

miR‑155 inhibitor reduces the proliferation and migration in osteosarcoma MG‑63 cells

Authors:
- Huicheng Lv
- Jun Guo
- Siqin Li
- Dianmin Jiang
View Affiliations

Affiliations: Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 404000, P.R. China, Department of Orthopaedics, The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010030, P.R. China, Department of Ultrasound, The People's Hospital of Inner Mongolia, Hohhot 010010, P.R. China, Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 404000, P.R. China
Published online on: September 1, 2014 https://doi.org/10.3892/etm.2014.1942
Pages: 1575-1580

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As the most common malignant primary bone tumor in childhood, osteosarcoma (OS) maintains a high recurrence, despite the signiﬁcant improvements in the overall survival rate of high‑grade OS patients during the recent decades. Therefore, a novel therapy strategy is required for OS treatment. Recently, various microRNAs (miRNAs or miRs) have been confirmed as deregulated in OS, and the miR‑155 dysregulation in OS has been discovered by the microarray analysis. In the present study, the regulation of miR‑155 on the OS cell proliferation, migration and invasion on the MG‑63 cells was explored in vitro. The miR‑155 mimics were found to promote cell proliferation, colony formation, migration and invasion significantly, compared to the control miRNA. An miR‑155 inhibitor was also used to evaluate whether miR‑155 served as a therapeutic target for OS. The results demonstrated that the miR‑155 inhibitor significantly reduced the proliferation, colony formation, migration and invasion of the MG‑63 OS cells. Thus, the study confirmed the oncogenic regulation on the OS progression of miR‑155, which could serve as a therapeutic target with an miR‑155 inhibitor.

View Figures

View References

1	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer treatment and research. 152:3–13. 2009. View Article : Google Scholar
2	Dorfman HD and Czerniak B: Bone cancers. Cancer. 75:203–210. 1995. View Article : Google Scholar : PubMed/NCBI
3	Meyers PA, Heller G, Healey J, et al: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 10:5–15. 1992.PubMed/NCBI
4	Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
6	Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 113:25–36. 2003. View Article : Google Scholar : PubMed/NCBI
7	Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
8	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nature Revs Cancer. 6:259–269. 2006. View Article : Google Scholar
9	Wang D, Qiu C, Zhang H, Wang J, Cui Q and Yin Y: Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One. 5:e130672010. View Article : Google Scholar
10	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ventura A and Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell. 136:586–591. 2009. View Article : Google Scholar : PubMed/NCBI
13	Spizzo R, Nicoloso MS, Croce CM and Calin GA: SnapShot: MicroRNAs in Cancer. Cell. 137:586–586 e581. 2009. View Article : Google Scholar : PubMed/NCBI
14	Zhou G, Shi X, Zhang J, Wu S and Zhao J: MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res. 41:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
15	Li Y, Zhang J, Zhang L, Si M, Yin H and Li J: Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling. Carcinogenesis. 34:1601–1610. 2013. View Article : Google Scholar : PubMed/NCBI
16	Asangani IA, Rasheed SA, Nikolova DA, et al: MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar
17	Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ziyan W, Shuhua Y, Xiufang W and Xiaoyun L: MicroRNA-21 is involved in osteosarcoma cell invasion and migration. Med Oncol. 28:1469–1474. 2011. View Article : Google Scholar : PubMed/NCBI
19	Montanini L, Lasagna L, Barili V, et al: MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93. Cell Oncol (Dordr). 35:29–41. 2012. View Article : Google Scholar : PubMed/NCBI
20	Huang G, Nishimoto K, Zhou Z, Hughes D and Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
21	Duan Z, Choy E, Harmon D, et al: MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
22	Liu LH, Li H, Li JP, et al: miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun. 416:31–38. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Cai X, Wang Y, Tang H, Tong D and Ji F: microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 24:1363–1369. 2010.PubMed/NCBI
24	Thayanithy V, Sarver AL, Kartha RV, et al: Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone. 50:171–181. 2012. View Article : Google Scholar : PubMed/NCBI
25	Eis PS, Tam W, Sun L, et al: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
26	Kluiver J, Poppema S, de Jong D, et al: BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 207:243–249. 2005. View Article : Google Scholar : PubMed/NCBI
27	Provisor AJ, Ettinger LJ, Nachman JB, et al: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 15:76–84. 1997.
28	Goorin AM, Schwartzentruber DJ, Devidas M, et al; Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 21:1574–1580. 2003. View Article : Google Scholar
29	Lauvrak SU, Munthe E, Kresse SH, et al: Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer. 109:2228–2236. 2013. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
32	Nagarajan R, Weigel BJ, Thompson RC and Perentesis JP: Osteosarcoma in the first decade of life. Med Pediatr Oncol. 41:480–483. 2003. View Article : Google Scholar : PubMed/NCBI
33	Bramwell VH, Burgers M, Sneath R, et al: A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 10:1579–1591. 1992.
34	Bacci G, Picci P, Ferrari S, et al: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 72:3227–3238. 1993. View Article : Google Scholar
35	Mora J, Cruz CO, Parareda A and de Torres C: Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Oncol. 31:723–729. 2009. View Article : Google Scholar : PubMed/NCBI
36	McTiernan A and Whelan JS: A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma. Sarcoma. 8:71–76. 2004. View Article : Google Scholar : PubMed/NCBI
37	Navid F, Willert JR, McCarville MB, et al: Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 113:419–425. 2008. View Article : Google Scholar : PubMed/NCBI
38	McGary EC, Weber K, Mills L, et al: Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 8:3584–3591. 2002.PubMed/NCBI
39	Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S and Chott A: Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol. 16:66–71. 2003. View Article : Google Scholar : PubMed/NCBI
40	Kubo T, Piperdi S, Rosenblum J, et al: Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer. 112:2119–2129. 2008. View Article : Google Scholar : PubMed/NCBI
41	Kaya M, Wada T, Akatsuka T, et al: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 6:572–577. 2000.PubMed/NCBI
42	Kolb EA, Kamara D, Zhang W, et al: R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer. 55:67–75. 2010.PubMed/NCBI
43	Manara MC, Nicoletti G, Zambelli D, et al: NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res. 16:530–540. 2010. View Article : Google Scholar : PubMed/NCBI
44	Pignochino Y, Grignani G, Cavalloni G, et al: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer. 8:1182009. View Article : Google Scholar
45	Zhang W, Qian JX, Yi HL, et al: The microRNA-29 plays a central role in osteosarcoma pathogenesis and progression. Mol Biol (Mosk). 46:622–627. 2012. View Article : Google Scholar : PubMed/NCBI